Nu Skin Enterprises (NYSE:NUS – Get Free Report) and Niagen Bioscience (NASDAQ:NAGE – Get Free Report) are both small-cap consumer staples companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.
Earnings and Valuation
This table compares Nu Skin Enterprises and Niagen Bioscience”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nu Skin Enterprises | $1.49 billion | 0.18 | $160.20 million | $1.10 | 5.00 |
| Niagen Bioscience | $129.42 million | 1.92 | $17.38 million | $0.18 | 17.33 |
Insider & Institutional Ownership
82.8% of Nu Skin Enterprises shares are owned by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are owned by institutional investors. 2.8% of Nu Skin Enterprises shares are owned by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings and price targets for Nu Skin Enterprises and Niagen Bioscience, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nu Skin Enterprises | 1 | 1 | 0 | 0 | 1.50 |
| Niagen Bioscience | 0 | 1 | 3 | 1 | 3.00 |
Niagen Bioscience has a consensus target price of $10.33, indicating a potential upside of 231.20%. Given Niagen Bioscience’s stronger consensus rating and higher possible upside, analysts clearly believe Niagen Bioscience is more favorable than Nu Skin Enterprises.
Profitability
This table compares Nu Skin Enterprises and Niagen Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nu Skin Enterprises | 3.78% | 7.47% | 4.21% |
| Niagen Bioscience | 12.39% | 17.95% | 13.17% |
Volatility & Risk
Nu Skin Enterprises has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500.
Summary
Niagen Bioscience beats Nu Skin Enterprises on 11 of the 15 factors compared between the two stocks.
About Nu Skin Enterprises
Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa and ageLOC LumiSpa iO; and nutricentials skin care products. The company also provides wellness products, such as LifePak nutritional supplements, ageLOC TR90 weight management system, and Beauty Focus Collagen+. In addition, it is involved in the research and product development of skin care products and nutritional supplements. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
About Niagen Bioscience
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.
